EUVIMEDEUVIMED entdecken
Crossref

Triptolide enhances oxaliplatin sensitivity by suppressing the JAK2/STAT3 pathway in cancer cells

Ruoxuan Lou, Guiqing Li, Ying Chen, Qin Liu, Lilin Huang, Xiaoying Zhang, Leyang Xiang, Yanfang Chen, Jianwei Jiang, Zhilong Liu, Zhendong Li, Qiang Li

Bioorganic Chemistry · 2026-11 · 183 · 110555

DOI: 10.1016/j.bioorg.2026.110555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Ruoxuan Lou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Basic Medical College of Jinan University, Guangzhou 510632, China. Hauptthemen laut MEDLINE: Phenanthrenes, Diterpenes, STAT3 Transcription Factor, Oxaliplatin. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Liver cancer and lung cancer are major causes of cancer-related deaths worldwide. Oxaliplatin is a first-line chemotherapeutic agent, but its efficacy is often limited by acquired resistance. PURPOSE: This study investigated whether triptolide (TPL), a bioactive compound derived from a traditional Chinese medicinal herb, enhances the sensitivity of cancer cells to oxaliplatin and explored the underlying molecular mechanism. METHODS: Human liver cancer (Huh-7) and lung cancer (A549) cell lines were used as experimental models. Western blotting was performed to assess the effects of oxaliplatin on the signal transducer and activator of transcription 3 (STAT3) pathway. Cells were treated with oxaliplatin alone, a STAT3 inhibitor, STAT3 small interfering RNA, TPL alone, or their combinations, both in vitro and in vivo. Molecular docking, drug affinity responsive target stability, cellular thermal shift assay, and surface plasmon resonance were employed to identify and validate the direct binding between TPL and STAT3. Immunoprecipitation was used to examine STAT3 ubiquitination levels. RESULTS: Oxaliplatin treatment activated the STAT3 pathway in cancer cells. Inhibition of STAT3 either by a pharmacological inhibitor or by small interfering RNA significantly enhanced cellular sensitivity to oxaliplatin. RNA sequencing analysis revealed that TPL modulated STAT3-related pathways. Combination of TPL and oxaliplatin produced synergistic antitumor effects in both cell-based and animal models. Mechanistically, TPL directly bound to STAT3 at the Lys244 and Lys318 residues, promoting its ubiquitination and subsequent degradation. CONCLUSION: TPL acts as a novel small-molecule STAT3 inhibitor that promotes STATA3 ubiquitination-mediated degration, representing a promising candidate to sensitize tumors to oxaliplatin-based therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenanthrenesDiterpenesSTAT3 Transcription FactorOxaliplatinAntineoplastic AgentsJanus Kinase 2HumansEpoxy CompoundsCell ProliferationDose-Response Relationship, DrugAnimalsDrug Screening Assays, AntitumorStructure-Activity RelationshipMiceMolecular StructureSignal Transduction

Stichwörter der Autor:innen

Chemotherapy resistanceOxaliplatinSTAT3 inhibitorTriptolide

Substanzen

triptolidePhenanthrenesDiterpenesSTAT3 Transcription FactorOxaliplatinEpoxy CompoundsSTAT3 protein, humanAntineoplastic AgentsJanus Kinase 2JAK2 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry, Basic Medical College of Jinan University, Guangzhou 510632, China.
  • Department of Pathology, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, 511400, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China; Department of Hepatobiliary Surgery, Lianjiang People's Hospital, Zhanjiang, Guangdong Province.. Electron…
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China. Electronic address: lizhendong@jnu.edu.cn.

Zitieren

APA

Lou, R., Li, G., Chen, Y., Liu, Q., Huang, L., Zhang, X., Xiang, L., Chen, Y., Jiang, J., Liu, Z., Li, Z., & Li, Q. (2026). Triptolide enhances oxaliplatin sensitivity by suppressing the JAK2/STAT3 pathway in cancer cells. Bioorganic Chemistry, 183, 110555. https://doi.org/10.1016/j.bioorg.2026.110555

Vancouver

Lou R, Li G, Chen Y, Liu Q, Huang L, Zhang X, et al. Triptolide enhances oxaliplatin sensitivity by suppressing the JAK2/STAT3 pathway in cancer cells. Bioorganic Chemistry. 2026;183:110555. doi:10.1016/j.bioorg.2026.110555

BibTeX
@article{Lou2026,
  author = {Lou, Ruoxuan and Li, Guiqing and Chen, Ying and Liu, Qin and Huang, Lilin and Zhang, Xiaoying and Xiang, Leyang and Chen, Yanfang and Jiang, Jianwei and Liu, Zhilong and Li, Zhendong and Li, Qiang},
  title = {Triptolide enhances oxaliplatin sensitivity by suppressing the JAK2/STAT3 pathway in cancer cells},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {183},
  pages = {110555},
  doi = {10.1016/j.bioorg.2026.110555}
}
Kostenlos starten →